Boston, MA -- (SBWIRE) -- 09/06/2013 -- At winstonsmallcap.com we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. Let have a Look on: (Cirrus Logic, Inc.(NASDAQ:CRUS), Spansion Inc. (NYSE:CODE), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Sonus Networks, Inc.(NASDAQ:SONS)
Cirrus Logic, Inc.(NASDAQ:CRUS) shares declined 1.41% to $23.75. The company on July 25 reported first-quarter profit of $20.64 million or $0.31 per share, up from $6.93 million or $0.10 per share in the same period last year. Revenues totaled $155.13 million, up from $99.01 million last year. Analysts expected revenues of $160.12 million.
Looking forward, the company has forecast second quarter revenues in the range of $170 million to $190 million. Analysts currently expect second-quarter revenues of $189.99 million.
How Should Investors Trade CRUS After The Recent Volatility? Get Free Report Here
Spansion Inc. (NYSE:CODE) stock dropped 2.48% to $10.60. The company on August 21 announced that its indirect wholly owned subsidiary, Spansion LLC, has agreed to sell $150 million aggregate principal amount of its 2.00% Senior Exchangeable Notes Due 2020 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The size of the offering was increased from the previously announced aggregate principal amount of $125 million.
How Should Investors Trade CODE After The Recent Volatility? Get Free Report Here
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shares climbed 0.66% to $3.84. The company on August 22 announced that the British Journal of Cancer has published the paper "A Multinational Phase 2 Study of Nanoliposomal Irinotecan Sucrosofate (PEP02, MM-398) for Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer" in its latest issue. The Phase 2 study evaluated MM-398 (liposomal irinotecan sucrosulfate) monotherapy in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy.
Is MACK A Good Buy After The Recent Price Movement? Find Out Here
Sonus Networks, Inc.(NASDAQ:SONS) shares gained 1.69% and closed at $3.62. The company on August 26 announced that as part of the Company's previously announced stock buyback program, it has agreed to repurchase approximately 3.1 million shares of the Company's common stock in a privately negotiated transaction with Empire Capital Management, L.L.C. ("Empire") at $3.50 per share, the market closing price on August 23, 2013, for a total purchase price of approximately $11 million. The Company will pay for the share repurchase using cash on hand.
Is SONS A Strong Buy? Get Advantage Of Our Free Trend Analysis Here
Here at Winston we focus on undervalued companies trading under $5. Right now the markets are surging and we are seeing an opportunity in micro-cap companies like we have never seen before. We focus on companies that we feel are trading at a discount to the market for various reasons. Enter your email and track our performance! We are sure you won’t sure you won’t be disappointed.
http://winstonsmallcap.com/and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as “WSC” or “we” or “us” or “our”). WSC publishes information (the “Information”) about publicly traded companies (the “Profiled Company” or the “Profiled Companies”) which has been obtained from various sources including publicly available sources on the internet. WSC does not undertake any due diligence or investigation of the Information it obtains or publishes.
Read Full Disclaimer at: http://winstonsmallcap.com/disclaimer
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)